Procalcitonin
Procalcitonin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
290 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 6 | 3 | 72 | 81 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 2 | 2 | 50 | 55 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 1 | — | 3 | 35 | 40 |
| Communicable diseases | D003141 | — | — | — | 1 | — | 1 | 35 | 37 |
| Toxemia | D014115 | — | — | — | — | 1 | 1 | 35 | 37 |
| Respiratory tract infections | D012141 | — | J06.9 | — | 1 | — | 1 | 18 | 20 |
| Bacterial infections | D001424 | — | A49 | — | — | — | 1 | 14 | 15 |
| Fever | D005334 | — | R50.9 | — | — | — | 1 | 9 | 10 |
| Community-acquired pneumonia | D000098968 | — | — | 1 | — | — | 1 | 7 | 9 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 2 | 1 | 6 | 9 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | — | A48.3 | 1 | 1 | 1 | — | 13 | 15 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 2 | — | 3 | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | — | — | 1 |
| Essential hypertension | D000075222 | — | I10 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Critical illness | D016638 | — | — | — | 1 | — | — | 9 | 10 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | 5 | 6 |
| Shock | D012769 | — | R57.1 | 1 | 1 | — | — | 5 | 6 |
| Chemotherapy-induced febrile neutropenia | D064146 | — | — | 1 | 1 | — | — | 1 | 2 |
| Aplastic anemia | D000741 | — | D61.9 | 1 | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract diseases | D012140 | — | — | 1 | — | — | — | 1 | 2 |
| Respiration disorders | D012120 | — | J00-J99 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 21 | 21 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | — | — | 10 | 10 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | — | 7 | 7 |
| Meningitis | D008581 | EFO_0000584 | G03 | — | — | — | — | 7 | 7 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 6 | 6 |
| Anastomotic leak | D057868 | — | — | — | — | — | — | 6 | 6 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | — | — | 5 | 5 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 5 | 5 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | — | — | 5 | 5 |
| Intraabdominal infections | D059413 | — | — | — | — | — | — | 5 | 5 |
Show 162 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Procalcitonin |
| INN | _ |
| Description | PROCALCITONIN |
| Classification | Protein |
| Drug class | vitamin D analogs |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 56645-65-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2207138 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | SV1QL0ZSJ9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use